Author

Peter S. Horanyi

UCB Pharma (Belgium)ORCID 0000-0003-2218-9986Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:cryo-EM· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Research Focus:protein structure prediction· 1 Research Focus:synaptic & neural circuits· 1

Frequent Co-Authors

Adrian HalliD· 2 shared Anshumali MittaliD· 2 shared Christian WolffiD· 2 shared Jonathan A. ColemaniD· 2 shared Laurent ProvinsiD· 2 shared Matthew F. MartiniD· 2 shared Michel R. GillardiD· 2 shared David L. SulzeriD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

Adrian HallORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Structural Determinants of Synaptic Vesicle Protein 2C Ligand Selectivity and Their Impact on Dopamine Release

Matthew F. Martin, Meghan L. Bucher, Se Joon Choi, Anshumali Mittal, Eugene V. Mosharov, Adrian Hall, Christian Wolff, Michel R. Gillard, Laurent Provins, Peter S. Horanyi, David L. Sulzer, Gary Wright Miller, Jonathan A. Coleman

This study presents cryo-EM structures of SV2C and its ligands, revealing structural differences that explain ligand selectivity and impact dopamine release.

bioRxiv · Sep 13, 2026 · PreprintBiochemistry

Mechanisms Underlying Allosteric Modulation of Antiseizure Medication Binding to Synaptic Vesicle Protein 2A (SV2A)

Anshumali Mittal, Matthew F. Martin, Laurent Provins, Adrian Hall, Marie Ledecq, Christian Wolff, Michel R. Gillard, Peter S. Horanyi, Jonathan A. Coleman

This paper reveals how UCB1244283 enhances BRV and LEV binding to SV2A by occupying an allosteric site, explaining its selectivity and potential for targeted therapeutics.

Proceedings of the National Academy of Sciences · Sep 2, 2025Peer-reviewedBiochemistry